Konstantinos Pateras
Overview
Explore the profile of Konstantinos Pateras including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Khan M, Islam M, Hassan J, Paul S, Islam M, Pateras K, et al.
PLoS One
. 2022 Jul;
17(7):e0262978.
PMID: 35819968
Background: The study was aimed to estimate the true prevalence of human tuberculosis (TB); identify risk factors and clinical symptoms of TB; and detect rifampicin (RIF) sensitivity in three study...
12.
Pateras K, Kostoulas P
BMC Med Res Methodol
. 2022 Apr;
22(1):91.
PMID: 35369874
Background: Tests have false positive or false negative results, which, if not properly accounted for, may provide misleading apparent prevalence estimates based on the observed rate of positive tests and...
13.
Kostoulas P, Meletis E, Pateras K, Eusebi P, Kostoulas T, Furuya-Kanamori L, et al.
Sci Rep
. 2021 Dec;
11(1):23775.
PMID: 34893634
Early warning tools are crucial for the timely application of intervention strategies and the mitigation of the adverse health, social and economic effects associated with outbreaks of epidemic potential such...
14.
Sagris D, Georgiopoulos G, Pateras K, Perlepe K, Korompoki E, Milionis H, et al.
J Am Heart Assoc
. 2021 Nov;
10(22):e022487.
PMID: 34755543
Background Available evidence supports an association between atrial high-rate episode (AHRE) burden and thromboembolic risk, but the necessary extent and duration of AHREs to increase the thromboembolic risk remain to...
15.
Chatzidou S, Kontogiannis C, Georgiopoulos G, Kosmopoulos M, Pateras K, Spartalis M, et al.
Pacing Clin Electrophysiol
. 2021 Jul;
44(9):1497-1503.
PMID: 34287980
Background: Radiofrequency catheter ablation remains the most effective management option for atrioventricular nodal reentry tachycardia (AVNRT). The risk of atrioventricular (AV) block requiring permanent pacemaker is substantial, but, currently, a...
16.
Tandaju J, Li W, Pateras K, Georgiopoulos G
Am J Emerg Med
. 2021 May;
50:799.
PMID: 33958246
No abstract available.
17.
Pateras K, Nikolakopoulos S, Roes K
Stat Med
. 2021 Apr;
40(12):2957-2974.
PMID: 33813759
In drug development programs, proof-of-concept Phase II clinical trials typically have a biomarker as a primary outcome, or an outcome that can be observed with relatively short follow-up. Subsequently, the...
18.
Sagris D, Ntaios G, Georgiopoulos G, Pateras K, Milionis H
Eur J Intern Med
. 2021 Jan;
85:130-132.
PMID: 33419661
No abstract available.
19.
Aimo A, Pateras K, Stamatelopoulos K, Bayes-Genis A, Lombardi C, Passino C, et al.
Cardiovasc Drugs Ther
. 2020 Oct;
35(5):1067-1076.
PMID: 33074526
Background: Sacubitril/valsartan, vericiguat, and the sodium-glucose co-transporter-2 inhibitors (SGLT2i) dapagliflozin and empagliflozin proved effective in phase 3 trials on heart failure with reduced ejection fraction (HFrEF). Methods: We compared the...
20.
Pateras K, Nikolakopoulos S, Roes K
Pharm Stat
. 2020 Aug;
20(1):39-54.
PMID: 32767452
In rare diseases, typically only a small number of patients are available for a randomized clinical trial. Nevertheless, it is not uncommon that more than one study is performed to...